首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children.
【24h】

Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children.

机译:幼儿造血移植后含有ABO不相容血浆和肝静脉闭塞性疾病的血小板输注。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Hepatic veno-occlusive disease is a major limiting factor of high-dose chemotherapy in children. The cells lining the hepatic vascular endothelium express blood group A and/or B antigens according to the patient's blood group. We designed a study evaluating the impact of platelet concentrates containing ABO-incompatible plasma transfused to young children with a high risk of hepatic veno-occlusive disease. METHODS: In all, 186 consecutive children (median age: 4 years, range: 0.75-17 years), treated with high-dose chemotherapy containing busulfan followed by hematopoietic stem cell transplantation for neuroblastoma (n=112) or brain tumor (n=74) between 1988 and 1998, were investigated. The main endpoint was the occurrence of hepatic veno-occlusive disease. Multivariate analysis was performed using a Cox's regression model with transfusion of platelet concentrates containing ABO-incompatible plasma as a time-dependent covariate. RESULTS: We found that 73 out of 186 (39%) children developed hepatic veno-occlusive disease after transplantation. Multivariate analysis demonstrated that two factors significantly increased the risk of hepatic veno-occlusive disease occurrence: transfusion of platelet concentrates containing ABO-incompatible plasma (P=0.003) and use of melphalan in the conditioning regimen (P=0.006). Conversely, the number of platelet concentrates transfusions per week, child's age, weight, sex, and use of cyclophosphamide in the conditioning regimen had no effect. CONCLUSIONS: Transfusion of platelet concentrates containing ABO-incompatible plasma increases the risk of hepatic veno-occlusive disease in young children treated with a busulfan-containing regimen. Binding of A and/or B antigens expressed on the surface of hepatic endothelial cells may promote this complication. Transfusion of platelet concentrates containing ABO-incompatible plasma should be avoided in these children.
机译:背景:肝静脉闭塞性疾病是儿童大剂量化疗的主要限制因素。根据患者的血型,位于肝血管内皮细胞内的细胞表达血型A和/或B抗原。我们设计了一项研究,评估了含有ABO不相容血浆的浓缩血小板对输注高风险肝静脉闭塞性疾病的幼儿的影响。方法:总共186例儿童(中位年龄:4岁,范围:0.75-17岁)接受了含有白消安的大剂量化疗,然后进行造血干细胞移植治疗神经母细胞瘤(n = 112)或脑瘤(n = 74)在1988年至1998年之间进行了调查。主要终点是肝静脉闭塞性疾病的发生。使用Cox回归模型进行多变量分析,并输注含有ABO不相容血浆的血小板浓缩液作为随时间变化的协变量。结果:我们发现186名儿童中有73名(39%)在移植后发生了肝静脉闭塞性疾病。多变量分析表明,两个因素显着增加了肝静脉闭塞性疾病发生的风险:输注含有ABO不相容血浆的浓缩血小板(P = 0.003)和在调理方案中使用美法仑(P = 0.006)。相反,每周输注浓缩血小板的次数,儿童的年龄,体重,性别以及在调理方案中使用环磷酰胺均无影响。结论:输注含有ABO不相容血浆的浓缩血小板会增加接受含环丁砜治疗方案的幼儿发生肝静脉阻塞性疾病的风险。肝内皮细胞表面表达的A和/或B抗原的结合可能会促进这种并发症。在这些儿童中,应避免输注含有ABO不相容血浆的浓缩血小板。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号